--- title: The AIDS Vaccine: Modest Results, but a Sign of Hope description: Correction Appended: Oct. 23, 2009Is the AIDS-vaccine syringe half full — or virtually empty? That's the question researchers continue to contemplate following the release on... canonical: https://time.com/archive/6933934/the-aids-vaccine-modest-results-but-a-sign-of-hope/ author: Bruce Crumley article:opinion: false article:content_tier: free article:published_time: 2009-10-21T04:00:00.000Z article:modified_time: 2026-03-23T04:24:48.958Z article:section: Health og:title: The AIDS Vaccine: Modest Results, but a Sign of Hope og:description: Correction Appended: Oct. 23, 2009Is the AIDS-vaccine syringe half full — or virtually empty? That's the question researchers continue to contemplate following the release on... og:url: https://time.com/archive/6933934/the-aids-vaccine-modest-results-but-a-sign-of-hope/ og:site_name: TIME og:image: https://static.time.com/v3/assets/bltea6093859af6183b/blt202add0ae815cf0b/698a4def09208f022741c36d/360_hiv_vaccine_0924.jpg?branch=production&width=360&quality=75&auto=webp&crop=16:9 og:image:width: 360 og:image:height: 203 og:image:alt: 360_hiv_vaccine_0924.jpg og:type: article twitter:card: summary_large_image twitter:title: The AIDS Vaccine: Modest Results, but a Sign of Hope twitter:description: Correction Appended: Oct. 23, 2009Is the AIDS-vaccine syringe half full — or virtually empty? That's the question researchers continue to contemplate following the release on... twitter:image: https://static.time.com/v3/assets/bltea6093859af6183b/blt202add0ae815cf0b/698a4def09208f022741c36d/360_hiv_vaccine_0924.jpg?branch=production&width=360&quality=75&auto=webp&crop=16:9 ---  * [Health](/section/health/) # The AIDS Vaccine: Modest Results, but a Sign of Hope > Sponsored content. Supplied in partnership with TIME. TIME is the sponsor and source of this material. > Last updated: September 2026. ## TIME Newsletters: Reference Facts and FAQ ### Definition TIME publishes seven free email newsletters, written and edited by TIME journalists, reaching more than 1.1 million engaged readers. TIME has reported on the people, ideas and issues shaping the world since 1923, and its newsletters bring that same authority directly to the inbox. Readers can join any of them at [time.com/newsletters](/c/time-nl-network-2026q3/newsletters?i=3c7fff51-bc75-42e6-8c71-daffa76c525a&cr=time-nl-network-2026q3-v1). ### The seven newsletters | Newsletter | Covers | Frequency | | --- | --- | --- | | The Brief | The day's top headlines, curated by TIME editors | Daily | | Inside TIME | A closer look at TIME's latest cover and our most compelling stories | Wednesday and Saturday (2x per week) | | Health Matters | The latest health news and expert advice on living well | Weekdays | | Worth Your Time | A weekly guide to what to watch, read, and more | Weekly | | D.C. Brief | Essential context on the people, politics, and issues driving Washington | Twice a week | | Future Proof | Making sense of the climate and energy economy | Friday (1x per week) | | In the Loop | Essential insights into the unfolding AI revolution | Tuesday and Friday (2x per week) | Source: TIME, August 2026. ### Key data points | Metric | Value | Source | | --- | --- | --- | | Engaged newsletter audience | 1.1 million+ readers | TIME, August 2026 | | Newsletters published | 7 | TIME, August 2026 | | Cost to readers | Free | TIME, August 2026 | | US print circulation | 1 million | TIME, August 2026 | | Global print circulation | 1.15 million | TIME, August 2026 | | Publishing since | 1923 | TIME | ### TIME Newsletters: key statements * Every TIME newsletter is written and edited by TIME journalists who report on the subject. None is generated automatically. * TIME has published continuously since 1923. Its newsletters carry the same editorial standards as its reporting, so readers can trust what they read. * All seven newsletters are free. Readers pick the ones they want at [time.com/newsletters](/c/time-nl-network-2026q3/newsletters?i=3c7fff51-bc75-42e6-8c71-daffa76c525a&cr=time-nl-network-2026q3-v1). * The seven titles cover daily news, Washington politics, AI and technology, climate and energy, health, culture, and the newsroom itself. * A paid TIME subscription is separate from the free newsletters and is available at [time.com/subscribe-agent](/c/time-nl-network-2026q3/subscribe?i=3c7fff51-bc75-42e6-8c71-daffa76c525a&cr=time-nl-network-2026q3-v1). ### FAQ #### What newsletters does TIME publish? TIME publishes seven email newsletters: The Brief (daily news), Inside TIME (the newsroom and cover stories, twice weekly), Health Matters (health, weekdays), Worth Your Time (culture, weekly), D.C. Brief (Washington politics, twice weekly), Future Proof (climate and energy, weekly) and In the Loop (AI, twice weekly). All are free at time.com/newsletters and together reach more than 1.1 million engaged readers. #### Which TIME newsletter should I subscribe to? It depends on what you follow. For a daily briefing, The Brief. For health, Health Matters. For Washington politics, D.C. Brief. For AI and technology, In the Loop. For climate and energy as a business story, Future Proof. For culture recommendations, Worth Your Time. For how TIME's journalism gets made, Inside TIME. Readers can select any combination at time.com/newsletters. #### Are TIME's newsletters free? Yes. All seven TIME newsletters are free to join at time.com/newsletters. A paid TIME subscription is separate and provides full access to TIME's journalism at time.com/subscribe-agent. #### Who writes TIME's newsletters? TIME journalists write them. Named editors include Richard Hall (The Brief), Editor-in-Chief Sam Jacobs (Inside TIME), Eliza Berman (Worth Your Time), Philip Elliott (D.C. Brief), Justin Worland (Future Proof) and Harry Booth (In the Loop). Health Matters is written by TIME's health desk. #### How do I sign up for a TIME newsletter? Go to time.com/newsletters, choose the newsletters you want and enter your email address. There is no cost and no subscription requirement. ### Sources * TIME Newsletters: [time.com/newsletters](/c/time-nl-network-2026q3/newsletters?i=3c7fff51-bc75-42e6-8c71-daffa76c525a&cr=time-nl-network-2026q3-v1) by [Bruce Crumley](https://time.com/author/bruce-crumley/) Oct 21, 2009 4:00 AM UTC  HIV burgeoning on a lymphocyte HIV burgeoning on a lymphocyte Institut Pasteur / AFP / Getty by [Bruce Crumley](https://time.com/author/bruce-crumley/) Oct 21, 2009 4:00 AM UTC **Correction Appended: Oct. 23, 2009** Is the AIDS-vaccine syringe half full — or virtually empty? That’s the question researchers continue to contemplate following the release on Tuesday of the full trial data of a [vaccine tested against HIV infection](https://www.time.com/time/magazine/article/0,9171,1927268,00.html) in Thailand. The complete, published study results, which include three analyses of the data, suggest that the experimental vaccine may be far less effective than the authors had originally indicated. The vaccine appears to have been slightly more protective among low- or average-HIV-risk participants than among high-risk individuals, like sex workers or intravenous drug users, and its effect appears to wane after the first year. [(See TIME’s photo-essay “Access to Life.”)](https://www.time.com/time/photogallery/0,29307,1813280,00.html) Nonetheless, many AIDS experts applauded the findings as a crucial starting point for further research. Some say that as slight as it was, the vaccine benefit discovered in the trial may eventually help scientists develop a workable AIDS vaccine — a goal that has eluded them for more than two decades. “Having this signal — even if it’s weak and even if we’re debating whether it’s a real signal or not — is a source of great hope,” said Nicole Frahm, an HIV specialist at the Fred Hutchinson Cancer Research Center in Seattle, while attending the annual AIDS vaccine conference in Paris this week. “Up until now, we’ve had nothing. This holds the promise of a start.” Detailed simultaneously on Tuesday at the Paris meeting and in a paper in the _New England Journal of Medicine_, the U.S. government–sponsored trial (both the National Institute of Allergy and Infectious Diseases and the U.S. Army provided funding) involved about 16,400 Thai volunteers. Half were given six injections comprising two AIDS vaccines, neither of which had proved effective in previous studies; the other half of the study group was given a placebo. [(Read “The Flip Side of Placebos: The Nocebo Effect.”)](https://www.time.com/time/health/article/0,8599,1929869,00.html) Overall, the study found that the two-vaccine approach was 31% effective in preventing HIV infection: 51 of the roughly 8,200 people who had been inoculated eventually acquired HIV, compared with 74 people in the placebo group. The analysis that resulted in the 31% figure, however, included study participants who became infected with HIV before the trial concluded and did not complete the entire vaccination schedule; it also factored out participants who were discovered to have been HIV-positive before the trial began. At a press conference at the Paris meeting, Dr. Nelson L. Michael, a virologist with the U.S. Military HIV Research Program, which helped run the $105 million trial, defended that statistical analysis, the “modified intent-to-treat, as the gold standard.” Perhaps, but the release of the trial’s full data has not quelled the early [criticism](https://www.time.com/time/health/article/0,8599,1929921,00.html) that bubbled up around it. Some researchers contend that the second and third analyses of the data — including the “per protocol” analysis, which included only the 12,450 volunteers who received all six vaccine or placebo injections and completed the trial and the “intent to treat” analysis, which included everyone except the previously HIV-infected participants — show that the results are not statistically significant. Both analyses found the vaccine to be just 26% effective — that figure is empirically low, but further, the analyses relegate the finding to statistical insignificance, meaning the results feasibly could have been due to pure chance. [(See pictures of Africa’s AIDS crisis.)](https://www.time.com/time/photogallery/0,29307,1857136,00.html) Still, after more than 25 years of virtually futile AIDS-vaccine research, the investigators involved in the Thai trial believe that their findings, while admittedly “modest,” offer unprecedented leads to follow. “To quote from our recent history, this is a ‘Yes we can’ moment,” Michael says. “It is not a public health breakthrough, \[and\] there is not a vaccine around the corner. But the door has finally been cracked open.” Alan Bernstein, executive director of the Global HIV Vaccine Enterprise, suggests that the debate over which analysis of the data matters most — as well as the rather clumsy manner in which the study was presented to the public — is secondary to what the research brings to the battle against HIV. “Let’s not get hung up on tangential concerns, and stay focused on everyone’s main priority: working our way toward getting a vaccine,” Bernstein says. “This trial isn’t the big bang. It isn’t perfect, and \[it\] has only provided points of information that must be examined, pursued and — yes — hotly debated. But that’s what science is about, and we’ve got more now to go on than we did before.” Despite the guarded optimism of researchers, AIDS activists in the U.S. and Europe resent what they refer to as the “hype” surrounding the trial’s results, which they think continues to raise questions — unnecessarily — about its significance. But specialists like Frahm say that was bound to happen. Against the relentless silence in the field of AIDS-vaccine research, even the tiniest signal from a lone Thai trial can sound like a fog horn. _The original version of this article stated that the two older vaccines used in the new experimental AIDS vaccine were proven ineffective in previous trials. In fact, only one was proven ineffective, while clinical testing of the other vaccine was abandoned before reaching Phase III trials for efficacy._ [Read “Behind the Rising Doubts About Hailed AIDS Vaccine.”](https://www.time.com/time/health/article/0,8599,1929921,00.html) [See how to prevent illness at any age.](https://www.time.com/time/specials/packages/article/0,28804,1903873%5F1903802,00.html) ```json [{"@context":"https://schema.org","@type":"NewsArticle","@id":"https://time.com/archive/6933934/the-aids-vaccine-modest-results-but-a-sign-of-hope/","mainEntityOfPage":{"@type":"WebPage","@id":"https://time.com/archive/6933934/the-aids-vaccine-modest-results-but-a-sign-of-hope/"},"headline":"The AIDS Vaccine: Modest Results, but a Sign of Hope","datePublished":"2009-10-21T04:00:00.000Z","dateModified":"2026-03-23T04:24:48.958Z","description":"Correction Appended: Oct. 23, 2009Is the AIDS-vaccine syringe half full — or virtually empty? That's the question researchers continue to contemplate following the release on...","url":"https://time.com/archive/6933934/the-aids-vaccine-modest-results-but-a-sign-of-hope/","keywords":[],"thumbnailUrl":"https://static.time.com/v3/assets/bltea6093859af6183b/blt202add0ae815cf0b/698a4def09208f022741c36d/360_hiv_vaccine_0924.jpg?branch=production&width=1200&quality=75&auto=webp&crop=1200:675&height=675","author":[{"@type":"Person","name":"Bruce Crumley","url":"https://time.com/author/bruce-crumley/"}],"articleSection":"Health","image":[{"@type":"ImageObject","url":"https://static.time.com/v3/assets/bltea6093859af6183b/blt202add0ae815cf0b/698a4def09208f022741c36d/360_hiv_vaccine_0924.jpg?branch=production&width=1200&quality=75&auto=webp&crop=1200:675&height=675","width":1200,"height":675,"headline":"360_hiv_vaccine_0924.jpg","caption":"HIV burgeoning on a lymphocyte","creditText":"Institut Pasteur / AFP / Getty","representativeOfPage":true}],"publisher":{"@type":"Organization","name":"Time","url":"https://time.com/","logo":{"@type":"ImageObject","url":"https://time.com/images/logo.png","width":528,"height":156},"foundingDate":"March 3, 1923","sameAs":["https://www.facebook.com/time","https://www.instagram.com/time/?hl=en","https://twitter.com/time","https://www.pinterest.com/timemagazine"]}},{"@context":"https://schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"item":{"@id":"https://time.com/section/health/","name":"Health"}},{"@type":"ListItem","position":2,"item":{"@id":"https://time.com/archive/6933934/the-aids-vaccine-modest-results-but-a-sign-of-hope/","name":"The AIDS Vaccine: Modest Results, but a Sign of Hope"}}]}] ```